TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients
TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for the treatment of inherited Epidermolysis Bullosa (EB). This trial marks a significant advancement in the quest for effective therapies for this challenging condition. The Phase 2 trial of AC-203 is […]